SciSparc Ltd
Company Profile
Business description
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company’s operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Contact
20 Raul Wallenberg Street
Tower A, 2nd Floor
Tel Aviv6971916
ISRT: +972 37175777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
stocks
Is this still an ASX share to own forever?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,140.50 | 11.00 | 0.12% |
| CAC 40 | 7,656.10 | 42.82 | -0.56% |
| DAX 40 | 23,625.66 | 144.67 | -0.61% |
| Dow JONES (US) | 45,316.53 | 304.76 | -0.67% |
| FTSE 100 | 9,204.98 | 11.89 | -0.13% |
| HKSE | 25,417.98 | 359.47 | 1.43% |
| NASDAQ | 21,621.71 | 85.98 | -0.40% |
| Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
| NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
| S&P 500 | 6,464.58 | 37.50 | -0.58% |
| S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
| SSE Composite Index | 3,812.51 | 46.64 | 1.24% |